Events

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 PM EDT

1 RACE-Approved Credit  

RACE# 27059-918761

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

7:00 PM

1 RACE-Approved Credit  

RACE# 27059-900255 

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 PM EDT

1 RACE-Approved Credit  

RACE# 27059-918761

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

7:00 PM EDT

1 RACE-Approved Credit  

RACE# 27059-900255 

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

6:30 PM CDT

1 RACE-Approved Credit  

RACE# 27059-918761

Unintentional feline weight loss is a common, vague clinical sign, with serious health repercussions if not identified & addressed proactively.  This presentation  will review the significance of weight loss, metabolic factors that put cats at higher risk, and a multimodal approach to management. The presentation will also explore pharmacologic intervention, including FDA approved medication. 

10:00 PM Eastern, 7:00 PM Pacific 

1 RACE-Approved Credit  

RACE# 27059-890381 

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

6:30 PM CDT

1 RACE-Approved Credit  

RACE# 27059-918761

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

6:30 PM EDT

1 RACE-Approved Credit  

RACE# 27059-918761

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

7:00 PM EDT

1 RACE-Approved Credit  

RACE# 27059-900255 

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

2:00 PM Eastern, 11:00 AM Pacific 

1 RACE-Approved Credit  

RACE# 27059-900255 

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

7:00 PM EDT

1 RACE-Approved Credit  

RACE# 27059-918761

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

7:00 PM MDT

1 RACE-Approved Credit  

RACE# 27059-918761

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

7:00 PM PDT

1 RACE-Approved Credit  

RACE# 27059-900255 

Feline hyperthyroidism is the most common endocrine disease affecting older cats. Prevalence has been reported as 10% in cats older than 10 years of age and is expected to rise. Left untreated, the disease can cause some potentially life-threatening metabolic disturbances. This presentation will review pathophysiology, diagnosis and treatment options in cats with feline hyperthyroidism. In addition, there are sections discussing co-management with chronic kidney disease and co-management with cardiovascular disease. 

7:00 PM Eastern, 4:00 PM Pacific 

1 RACE-Approved Credit  

RACE# 27059-893812 

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

12:00 PM Eastern, 9:00 AM Pacific 

1 RACE-Approved Credit  

RACE# 27059-918761

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

7:00 PM CDT

1 RACE-Approved Credit  

RACE# 27059-918761

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

7:00 PM CDT

1 RACE-Approved Credit  

RACE# 27059-918761

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

6:30 PM EDT

1 RACE-Approved Credit  

RACE# 27059-918761

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

7:00 PM CDT

1 RACE-Approved Credit  

RACE# 27059-918761

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

7:00 PM CDT

1 RACE-Approved Credit  

RACE# 27059-900255 

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

07:00 CDT

1 RACE-Approved Credit  

RACE# 27059-918761

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

7:00 PM EDT

1 RACE-Approved Credit  

RACE# 27059-918761

Canine otitis externa is one of the most frequently encountered conditions in small animal veterinary practice. This presentation explores the causes of canine otitis externa including the predisposing, primary and perpetuating factors, the importance of otic cytology, and the essential treatment modalities to help ensure clinical resolution. The development of a long-term maintenance cleaning and allergy management plan will also be discussed.

10:00 PM Eastern, 07:00 PM Pacific 

1 RACE-Approved Credit  

RACE# 27059-805774

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

7:00 P.M. CDT

1 RACE-Approved Credit  

RACE# 27059-900255 

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

7:00 PM EDT

1 RACE-Approved Credit  

RACE# 27059-918761

This presentation provides a review of Canine Hypoadrenocorticism (Addison’s Disease); the topics include pathophysiology, signalment, clinical signs, diagnostics, treatment, and monitoring.  Cases will be discussed to reinforce your diagnostic confidence. 

7:00 PM Eastern, 4:00 PM Pacific 

1 RACE-Approved Credit  

RACE# 27059-894090 

This presentation breaks down the complex mechanisms of bisphosphonates as a drug class and their use in managing the clinical signs of navicular syndrome in horses. The second half of the presentation explores the clinical features of non-nitrogenous bisphosphonates including their efficacy and safety in real world field applications. 

12:00 PM Eastern, 9:00 AM Pacific 

1 RACE-Approved Credit  

RACE# 27059-763173 

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

10:00 PM Eastern, 7:00 PM Pacific 

1 RACE-Approved Credit  

RACE# 27059-918761

This presentation will review the components of an appropriate fluid plan including why fluids are useful, which fluid, and how to calculate the correct volume and rate.  In addition, monitoring guidelines to ensure the fluid plan is adequate and appropriate will be discussed.  Participants will also learn about the endothelial glycocalyx and its important role in maintaining normal vascular function. 

7:00 PM Eastern, 4:00 PM Pacific 

1 RACE-Approved Credit  

RACE# 27059-743915 

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

12:00 PM Eastern, 9:00 AM Pacific 

1 RACE-Approved Credit  

RACE# 27059-900255 

Part 1: In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

Part 2: This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events.

7:00 PM EST

2 RACE-Approved Credit  

Canine Hyperadrenocorticism (Cushing’s Disease) can be a challenging yet rewarding disease to manage. This presentation will review all aspects of Cushing’s: basic pathophysiology, clinical signs, diagnostics, differentiating tests, treatment and monitoring. A series of cases to increase  understanding of managing Cushing’s patients will be presented and the final  section highlights ways to  enhance owner compliance. 

10:00 PM Eastern, 7:00 PM Pacific 

1.5 RACE-Approved Credits  

RACE# 27059-869593 

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

2:00 PM Eastern, 11:00 AM Pacific 

1 RACE-Approved Credit  

RACE# 27059-918761

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events. 

7:00 PM Eastern, 4:00 PM Pacific 

1 RACE-Approved Credit  

RACE# 27059-900255 

Unintentional feline weight loss is a common, vague clinical sign, with serious health repercussions if not identified & addressed proactively.  This presentation  will review the significance of weight loss, metabolic factors that put cats at higher risk, and a multimodal approach to management. The presentation will also explore pharmacologic intervention, including FDA approved medication. 

12:00 PM Eastern, 9:00 AM Pacific 

1 RACE-Approved Credit  

RACE# 27059-890381 

In this educational presentation, we will discuss sedation in dogs. The foundation will be set by reviewing the basic physiology behind commonly used sedatives in dogs. We will discuss the most commonly used sedatives and reversal agents, and introduce the novel sedative Zenalpha (medetomidine and vatinoxan hydrochlorides).

10:00 PM Eastern, 7:00 PM Pacific 

1 RACE-Approved Credit  

RACE# 27059-918761